List view / Grid view
2 December 2025 | By Emerson
Join this webinar to discover how the pharmaceutical industry can move towards sustainable autonomous operations by implementing solutions that enhance pipeline acceleration, flexible manufacturing, operational integrity and real-time release.
As well as the new safety warnings for the Duchenne muscular dystrophy gene therapy, the biopharma company also faced a new, more restrictive licence for the treatment.
uniQure’s positive topline data “are the most convincing in the field to date” and indicate the gene therapy’s potential disease-modifying effects.
Advances cell therapy and gene therapy candidates, with both showing neurorestorative potential against the disease.
From groundbreaking cell and gene therapies to cost-effective drug delivery innovations, Europe is emerging as a hub for life-changing therapies. Explore expert insights and innovative solutions shaping the pharmaceutical industry.
EPR Issue 3 includes articles on microbiology, downstream processing, manufacturing, drug formulation and more.
2 September 2025 | By FUJIFILM Wako Europe GmbH
Watch this webinar to find out how RT-rt PCR is revolutionising sterility testing and discover a unique approach that provides reliable one-day results and enhanced sensitivity and detection capabilities.
Will expand the company’s CAR T-cell therapy footprint and gain access next generation in vivo technology.
The German pharma company’s BioXcellence arm will supply the drug substance for AnGes’ peripheral arterial disease treatment Collategene.
Further to its potential in Stargardt disease, if approved, the one-time gene therapy could become standard of care for retinitis pigmentosa, alongside other retinal degenerative diseases.
CBER head makes surprise comeback just weeks after his abrupt resignation.
11 August 2025 | By Entegris
This webinar explores the design and implementation of pre use post sterilisation integrity test assemblies (PUPSIT) in sterile filtration processes to ensure regulatory compliance while minimising operational risk.
But the impact of George Tidmarsh’s CBER appointment after Vinay Prasad’s abrupt resignation remains to be seen.
The landmark regulation establishes a future where highly personalised treatments are part of routine care, says MHRA’s Chief Executive.
The study represents the first time the injectable gene therapy has been evaluated in teenagers and adults.
